IP Library › Granted Patent US 7,332,519
Granted Patent B2
US 7,332,519 · App. 11/019,372 · Granted Feb 19, 2008

Spirocyclic cyclohexane compounds

Assignee: Gruenenthal GmbH
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,332,519
App. No.
11/019,372
Granted
Feb 19, 2008
Kind
B2
Abstract

Spirocyclic cyclohexane compounds, methods for their production, pharmaceutical compositions containing these compounds, and the use of these spirocyclic cyclohexane compounds for treating conditions associated with the nociceptin/ORL1 receptor system, e.g. pain, drug withdrawal, anxiety, etc.

Claims (100)

1. A spirocyclic cyclohexane compound corresponding to formula I

wherein

R 1 and R 2 independently represent H; CHO; respectively saturated or unsaturated, branched or unbranched, singly or multiply substituted or unsubstituted C 1-5 alkyl; respectively saturated or unsaturated, singly or multiply substituted or unsubstituted C 3-8 cycloalkyl; or respectively singly or multiply substituted or unsubstituted aryl, C 3-8 cycloalkyl or heteroaryl bound by C 1-3 alkyl; or

R 1 and R 2 together represent CH 2 CH 2 OCH 2 CH 2 , CH 2 CH 2 NR 11 CH 2 CH 2 or (CH 2 ) 3-6 ;

wherein R 11 represents H; respectively saturated or unsaturated, branched or unbranched, singly or multiply substituted or unsubstituted C 1-5 alkyl; respectively saturated or unsaturated, singly or multiply substituted or unsubstituted C 3-8 cycloalkyl; respectively singly or multiply substituted or unsubstituted aryl or heteroaryl; or respectively singly or multiply substituted or unsubstituted aryl, C 3-8 cycloalkyl or heteroaryl bound by C 1-3 alkyl;

R 3 represents respectively unsubstituted or singly or multiply substituted heteroaryl or heteroaryl bound by C 1-3 ;

W represents NR 4 , O or S and

wherein R 4 represents H; saturated or unsaturated, branched or unbranched, unsubstituted or singly or multiply substituted C 1-5 alkyl; respectively substituted or unsubstituted aryl or heteroaryl; respectively singly or multiply substituted or unsubstituted aryl, heteroaryl or cycloalkyl bound by a C 1-3 alkyl group; COR 12 ; SO 2 R 12 ;

wherein R 12 represents H; respectively saturated or unsaturated, branched or unbranched, singly or multiply substituted or unsubstituted C 1-5 alkyl; respectively saturated or unsaturated, singly or multiply substituted or unsubstituted C 3-8 cycloalkyl; respectively singly or multiply substituted or unsubstituted aryl or heteroaryl; or respectively singly or multiply substituted or unsubstituted aryl, C 3-8 cycloalkyl or heteroaryl bound by C 1-3 alkyl; OR 13 ; NR 14 R 15 ;

R 5 represents ═O; H; COOR 13 , CONR 13 , OR 13 ; saturated or unsaturated, branched or unbranched, unsubstituted or singly or multiply substituted C 1-5 alkyl; saturated or unsaturated, unsubstituted or singly or multiply substituted C 3-8 cycloalkyl; unsubstituted or singly or multiply substituted aryl or heteroaryl; or unsubstituted or singly or multiply substituted aryl, C 3-8 cycloalkyl or heteroaryl bound by C 1-3 alkyl;

R 6 represents H; F, Cl, NO 2 , CF 3 , OR 13 , SR 13 , SO 2 R 13 , SO 2 OR 13 , CN, COOR 13 , NR 14 R 15 ; saturated or unsaturated, branched or unbranched, unsubstituted or singly or multiply substituted C 1-5 alkyl; saturated or unsaturated, unsubstituted or singly or multiply substituted C 3-8 cycloalkyl; unsubstituted or singly or multiply substituted aryl or heteroaryl; or unsubstituted or singly or multiply substituted aryl, C 3-8 cycloalkyl or heteroaryl bound by C 1-3 alkyl; or

R 5 and R 6 together represent (CH 2 ) n where n=2, 3, 4, 5 or 6, wherein individual hydrogen atoms may also be replaced by F, Cl, Br, I, NO 2 , CF 3 , OR 13 , CN or C 1-5 alkyl;

R 7 , R 8 , R 9 and R 10 independently represent H, F, Cl, Br, I, NO 2 , CF 3 , OR 13 , SR 13 , SO 2 R 13 , SO 2 OR 13 , CN, COOR 13 , NR 14 R 15 ; unsubstituted or singly or multiply substituted C 1-5 alkyl, C 3-8 cycloalkyl; unsubstituted or singly or multiply substituted aryl or heteroaryl; or unsubstituted or singly or multiply substituted aryl, C 3-8 cycloalkyl or heteroaryl bound by C 1-3 alkyl;

wherein R 13 represents H; respectively saturated or unsaturated, branched or unbranched, unsubstituted or singly or multiply substituted C 1-5 alkyl; respectively saturated or unsaturated, unsubstituted or singly or multiply substituted C 3-8 cycloalkyl; unsubstituted or singly or multiply substituted aryl or heteroaryl; or unsubstituted or singly or multiply substituted aryl, C 3-8 cycloalkyl or heteroaryl bound by C 1-3 alkyl; and

R 14 and R 15 independently represent H; respectively saturated or unsaturated, branched or unbranched, unsubstituted or singly or multiply substituted C 1-5 alkyl; or respectively saturated or unsaturated, unsubstituted or singly or multiply substituted C 3-8 cycloalkyl; unsubstituted or singly or multiply substituted aryl or heteroaryl; or unsubstituted or singly or multiply substituted aryl, C 3-8 cycloalkyl or heteroaryl bound by C 1-3 alkyl; or

R 14 and R 15 together form CH 2 CH 2 OCH 2 CH 2 , CH 2 CH 2 NR 16 CH 2 CH 2 or (CH 2 ) 3-6 ,

wherein R 16 represents H; saturated or unsaturated, branched or unbranched, unsubstituted or singly or multiply substituted C 1-5 alkyl;

X represents O, S, SO, SO 2 or NR 17 ;

wherein R 17 represents H; saturated or unsaturated, branched or unbranched C 1-5 alkyl; COR 12 or SO 2 R 12 ,

or a physiologically acceptable salt thereof.

2. A compound according to claim 1 , wherein said compound is present in the form of a racemic mixture or a mixture of diastereomers or enantiomers.

3. A compound according to claim 1 , wherein said compound is present in the form of a pure diastereomer.

4. A compound according to claim 1 , wherein R 1 and R 2 independently represent H, branched or unbranched, saturated or unsaturated, unsubstituted or singly or multiply substituted C 1-5 alkyl, or CHO.

5. A compound according to claim 1 , wherein R 3 represents unsubstituted or singly or multiply substituted heteroaryl.

6. A compound according to claim 1 , wherein R 5 represents H, branched or unbranched, unsubstituted or singly or multiply substituted C 1-5 alkyl, or COOR 13 , and R 6 represents H or C 1-5 alkyl.

7. A compound according to claim 1 , wherein R 7 , R 8 , R 9 and R 10 independently represent H; branched or unbranched, unsubstituted or singly or multiply substituted C 1-5 alkyl; F, Cl, Br, I, CF 3 , OH, OCH 3 , NH 2 , COOH, COOCH 3 , NHCH 3 , N(CH 3 ) 2 or NO 2 .

8. A compound according to claim 1 , wherein

W represents NR 4 , O or S;

X represents O, S, SO, SO 2 or NR 17 ;

R 1 and R 2 independently represent H; branched or unbranched, singly or multiply substituted or unsubstituted C 1-4 alkyl; or CHO;

R 3 represents unsubstituted or singly or multiply substituted heteroaryl;

R 4 represents H, singly or multiply substituted or unsubstituted C 1-3 alkyl, or CO(CH 2 ) m H, wherein m=0 to 2;

R 5 and R 6 each represent H; and

R 7 , R 8 , R 9 and R 10 independently of one another represent H; respectively branched or unbranched, saturated or unsaturated, unsubstituted or singly or multiply substituted C 1-5 alkyl or OC 1-3 alkyl; F, Cl, Br, I, CF 3 , OH, SH, SCH 3 , OCH 3 , NH 2 , COOH, COOCH 3 , NHCH 3 , N(CH 3 ) 2 or NO 2 .

9. A compound according to claim 1 , wherein R 1 and R 2 independently represent H or CH 3 , and at least one of R 1 and R 2 is not H.

10. A compound according to claim 1 , wherein

W represents NR 4 ;

X represents O;

R 1 and R 2 independently represent H; branched or unbranched, singly or multiply substituted or unsubstituted C 1-4 alkyl; or CHO;

R 3 represents unsubstituted or singly or multiply substituted heteroaryl;

R 4 represents H, singly or multiply substituted or unsubstituted C 1-3 alkyl, or CO(CH 2 ) m H, wherein m=0 to 2;

R 5 and R 6 each represent H; and

R 7 , R 8 , R 9 and R 10 independently represent H; respectively branched or unbranched, saturated or unsaturated, unsubstituted or singly or multiply substituted C 1-5 alkyl or OC 1-3 alkyl; F, Cl, Br, I, CF 3 , OH, SH, SCH 3 , OCH 3 , NH 2 , COOH, COOCH 3 , NHCH 3 , N(CH 3 ) 2 or NO 2 .

11. A compound according to claim 1 , wherein R 3 represents thienyl or pyridyl.

12. A compound according to claim 1 , wherein

R 5 represents H, CH 3 , COOCH 3 or CH 2 OH;

R 6 represents H; and

at least two of R 7 , R 8 , R 9 and R 10 represent H and the others are independently selected from the group consisting of H; branched or unbranched, unsubstituted or singly or multiply substituted C 1-5 alkyl; F, Cl, Br, I, OH, OCH 3 , COOH, COOCH 3 , NH 2 , NHCH 3 , N(CH 3 ) 2 and NO 2 .

13. A compound according to claim 1 , wherein R 1 and R 2 represent CH 3 , and R 3 represents thienyl or pyridyl.

14. A compound according to claim 1 , wherein

W represents NR 4 ;

X represents O, and

R 4 represents H, CH 3 , C 2 H 5 , acetyl, phenyl, benzyl or COR 12 .

15. A compound according to claim 1 , selected from the group consisting of:

1,1-[3-dimethylamino-3-(pyridin-2-yl)pentamethylene]-3,4-dihydro-1H-2,9-diazafluorene,

2-acetyl-1,1-[3-dimethylamino-3-(pyridin-2-yl)pentamethylene]-3,4-dihydro-1H-2,9-diazafluorene,

1,1-[3-dimethylamino-3-(pyridin-2-yl)pentamethylene]-3,4-dihydro-1H-2-oxa-9-thiafluorene,

1,1-[3-dimethylamino-3-(pyridin-2-yl)pentamethylene]-1,3,4,9-tetrahydropyrano-[3,4-b]indole hemicitrate, non-polar diastereoisomer,

1,1-[3-dimethylamino-3-(pyridin-2-yl)pentamethylene]-1,3,4,9-tetrahydropyrano-[3,4-b]indole citrate, polar diastereoisomer,

1,1-[3-dimethylamino-3-(2-thienyl)pentamethylene]-1,3,4,9-tetrahydro-pyrano[3,4-b]indole dimethanesulfonate,

1,1-[3-dimethylamino-3-(2-thienyl)pentamethylene]-1,3,4,9-tetrahydro-pyrano[3,4-b]indole citrate,

1,1-[3-dimethylamino-3-(3-thienyl)pentamethylene]-1,3,4,9-tetrahydro-pyrano[3,4-b]indole hemicitrate,

1,1-[3-dimethylamino-3-(3-thienyl)pentamethylene]-1,3,4,9-tetrahydro-pyrano[3,4-b]indole citrate,

1,1-[3-dimethylamino-3-(2-thienyl)pentamethylene]-1,3,4,9-tetrahydro-pyrano[3,4-b]-6-fluoroindole hemicitrate,

1,1-[3-dimethylamino-3-(2-thienyl)pentamethylene]-1,3,4,9-tetrahydro-pyrano[3,4-b]-6-fluoroindole citrate,

1,1-[3-dimethylamino-3-(3-thienyl)pentamethylene]-1,3,4,9-tetrahydro-pyrano[3,4-b]-6-fluoroindole dimethanesulfonate,

1,1-[3-dimethylamino-3-(3-thienyl)pentamethylene]-1,3,4,9-tetrahydro-pyrano[3,4-b]-6-fluoroindole hemicitrate,

1,1-[3-methylamino-3-(2-thienyl)pentamethylene]-1,3,4,9-tetrahydro-pyrano[3,4-b]indole citrate,

1,1-[3-methylamino-3-(2-thienyl)pentamethylene]-1,3,4,9-tetrahydro-pyrano[3,4-b]-6-fluoroindole citrate,

1,1-[3-methylamino-3-(3-thienyl)pentamethylene]-1,3,4,9-tetrahydro-pyrano[3,4-b]indole citrate, and

1,1-[3-methylamino-3-(3-thienyl)pentamethylene]-1,3,4,9-tetrahydro-pyrano[3,4-b]-6-fluoroindole citrate;

or a mixture of two or more of the foregoing.

16. A process for producing a compound according to claim 1 , said process comprising reacting an educt corresponding to formula A

wherein R 01 and R 02 have the meaning given in claim 1 for R 2 or represent a protective group, and R 3 has the meaning given in claim 1 for R 3 ,

with addition of an acid or a trimethylsilylester of an acid, in a solvent,

with an educt corresponding to formula B

 wherein W, X and R 5 to R 10 have the meanings given in claim 1 .

17. A process according to claim 16 , wherein said acid or trimethylsilylester of an acid is selected from the group consisting of trifluoromethane sulfonic acid trimethylsilylester, trifluoromethane sulfonic acid, acetic acid, phosphoric acid, methane sulfonic acid, and trifluoroacetic acid, and said solvent is selected from the group consisting of dichloroethane, dichloromethane, chloroform, acetonitrile, diethyl ether and nitromethane.

18. A process for producing a spirocyclic cyclohexane compound according to claim 1 , wherein X represents NR 17 , and R 17 represents COR 12 or SO 2 R 2 , said process comprising reacting a compound corresponding to formula I in which X represents NH,

with the addition of a base,

with an anhydride or an acid chloride.

19. A process according to claim 18 , wherein said base is triethylamine, and said reaction is carried out under microwave irradiation.

20. A process for producing a spirocyclic cyclohexane compound according to claim 1 , wherein X represents SO or SO 2 , said process comprising oxidizing a compound corresponding to formula I in which X represents S, with an oxidizing agent.

21. A process according to claim 20 , wherein said oxidizing agent is H 2 O 2 .

22. A process for producing a spirocyclic cyclohexane compound corresponding to formula Ib

said process comprising

reacting thiophen-3-yl-acetonitrile with an acrylic ester or a 3-bromopropionic acid ester,

hydrolyzing and decarboxylating the ester,

providing the hydrolyzed and decarboxylated product with protective groups,

converting the nitrile group into a carboxylic acid group and then into an isocyanate by hydrolysis followed by reaction with a reducing agent,

removing protective groups by addition of acid or a trimethylsilylester of an acid, and

reacting the resulting product in a solvent with an educt of general formula B

 wherein W, X and R 5 to R 10 have the meanings given in claim 1 .

23. A process according to claim 22 , wherein the reducing agent is lithium aluminium hydride, the acid or trimethylsilylester is selected from the group consisting of trifluoromethane sulfonic acid trimethylsilylester, trifluoromethane sulfonic acid, acetic acid, phosphoric acid, methane sulfonic acid and trifluoroacetic acid, and the solvent is selected from the group consisting of dichloroethane, dichloromethane, chloroform, acetonitrile, diethyl ether and nitromethane.

24. A pharmaceutical composition comprising a spirocyclic cyclohexane compound according to claim 1 , and at least one pharmaceutical auxiliary agent.

25. A method of treating pain in a patient in need thereof, said method comprising administering to said patient a pharmaceutically effective amount of a compound according to claim 1 .

26. A method according to claim 25 , wherein said pain is acute pain, neuropathic pain or chronic pain.

27. A method of treating withdrawal symptoms of opioid abuse, dependency or addiction, in a patient in need thereof, said method comprising administering to said patient a pharmaceutically effective amount of a compound according to claim 1 .

28. A method according to claim 27 , wherein said condition is opioid addiction.

29. A method according to claim 27 , wherein said compound, is co-administered with an opioid to reduce the addiction potential of the opioid.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 9, 2005
From: HINZE, CLAUDIA; SUNDERMANN, BERND; OBERBOERSCH, STEFAN; ENGLBERGER, WERNER; FRIDERICHS, ELMAR; FRORMANN, SVEN; KOEGEL, BABETTE-YVONNE; LINZ, KLAUS; MERLA, BEATRIX; SAUNDERS, DEREK; SCHROEDER, WOFGANG; SCHICK, HANS; HENKEL, BIRGITTA; SONNENSCHEIN, HELMUT
To: GRUENENTHAL GMBH
Reel/Frame 016538/0816 →
Priority Claims (1)
DE 103 60 792 · Dec 23, 2003 · national
Continuity (1)
Related Publication 20050192333A1 · Sep 1, 2005